Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
2024 · Blood Cancer Journal · 89 citations
https://doi.org/10.1038/s41408-024-01003-z
M
Maurizio Zangari
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
512
Papers
19.2K
Citations
70
h-index
172
i10-index
Maurizio Zangari is an academic researcher from Winthrop Rockefeller Foundation. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Cancer Treatment and Pharmacology. The author has an h-index of 70, co-authored 436 publications.
ORCID: 0000-0002-1720-3854Papers by this author
worksThe level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myeloma
2017 · Haematologica · 78 citations
https://doi.org/10.3324/haematol.2017.168872
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
2017 · Blood Cancer Journal · 59 citations
https://doi.org/10.1038/bcj.2017.12
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
2020 · Blood Cancer Journal · 37 citations
https://doi.org/10.1038/s41408-020-0336-z
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
2019 · Blood Cancer Journal · 36 citations
https://doi.org/10.1038/s41408-019-0226-4
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
2016 · Blood Cancer Journal · 34 citations
https://doi.org/10.1038/bcj.2016.64
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat